... the knowledge base of the clinical presentation and growth response to recombinant human growth hormone (rhGH) of patients carrying such variants. Methods: Retrospective case series of patients with pathogenic heterozygous IGF1 variants. Results: Nine patients from six families were included, harbouring five...

... from 34 consanguineous families was collected by six referral centres of paediatric endocrinology (inclusion criteria: short stature and parental consanguinity). In 18 patients (12 families, group 1), the clinical features suggested a specific genetic defect in the growth hormone (GH) insulin-like...

.... It is characterized by extreme short stature with adult height (AH) in males typically less than 150 cm and in females less than 130 cm. Our objective was to evaluate the effect and safety of growth hormone (GH) treatment in 6 patients with pycnodysostosis treated according to the Dutch national pycnodysostosis...

.... 2024 Noonan syndrome Adult height Body mass index Growth hormone Noonan syndrome (NS) is an autosomal dominant disorder with an estimated incidence of 1:1,000–1:2,500 live births [ 1 ]. It is characterized by a distinctive facial appearance, congenital heart defects, thoracic...

... energy intake and energy expenditure are important components. Previous studies described a decreased resting energy expenditure (REE) in growth hormone (GH)-untreated children with PWS. In short-term studies, no difference in REE was found between GH-treated and untreated children with PWS. However...

... with characteristically accelerated bone age (BA) maturation and/or early-onset osteoarthritis (OA). Methods: The objective of this study was to describe phenotype, analyze genotype-phenotype correlations, and assess the response of growth hormone (GH) treatment in children with a heterozygous ACAN variant. Thirty-six...

...Michel Polak; Béatrice Demaret; Robin Henocque; Lylia Chachoua; Samuel Aballea; Marwa Mezghani; Daria La Torre; Lara Salvi; Philippe Touraine Introduction: The aim of this study was to identify drivers of preference for growth hormone deficiency (GHD) treatment in French children...

.... 2023 Prader-Willi syndrome Children Infants Growth hormone Ghrelin Prader-Willi syndrome (PWS) is a rare syndrome caused by the lack of expression of the paternally derived chromosome 15q11-q13, due to a paternal deletion or maternal uniparental disomy, and in rare cases...

...Régis Coutant; Bruno Leheup; Marc Nicolino; Jean-Pierre Salles Introduction: Growth hormone (GH) therapy improves height outcomes in short children born small for gestational age (SGA); however, real-world data on long-term GH exposure are few. Methods: We report results from an observational study...

... it and distinguish it from other anterior pituitary hormones. With relatively pure growth hormone (GH), its biological activity in growth promotion and as a metabolic hormone were studied, and species specificity became apparent: primate GH was the only GH active in man. Human GH was prepared from cadaveric...

...Reiko Horikawa; Toshiaki Tanaka; Yukihiro Hasegawa; Tohru Yorifuji; David Ng; Ron G. Rosenfeld; Yuko Hoshino; Akifumi Okayama; Daisuke Shima; Roy Gomez; Aleksandra Pastrak; Orlando Castellanos Introduction: Somatrogon is a long-acting recombinant human growth hormone being developed as a once...

... the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy to lonapegsomatropin. Methods: This multicenter, open-label, 26-week phase 3 trial took place at 28 sites across 4 countries...

...Valentina Pampanini; Annalisa Deodati; Elena Inzaghi; Stefano Cianfarani Background: Daily recombinant human growth hormone (rhGH) is approved and marketed worldwide to treat children and adults with GH deficiency and other conditions. Efficacy of rhGH therapy is influenced by several variables...

...George M. Bright; Peter A. Morris; Ron G. Rosenfeld Background: In most cases, the growth hormone stimulation test is a necessary component for the diagnosis of growth hormone deficiency (GHD) in children. Diagnostic testing can lead to unnecessary treatment of children with false-positive test...

...David B. Allen; Nadia Merchant; Bradley S. Miller; Philippe F. Backeljauw Background: Longitudinal bone growth is regulated by multiple endocrine signals (e.g., growth hormone, insulin-like growth factor I, estrogen, and androgen) and local factors (e.g., fibroblast growth factors...

... of this study was to evaluate catch-up growth and cardiovascular markers before and during growth hormone (rhGH) treatment in KS children. Methods: This prospective study included 18 children whose KS was genetically established. Each KS subject received rhGH for a period of 2 years. Several measurements were...

... the normal range during childhood, adolescence, and adulthood. Turner syndrome Childhood Growth hormone Near-adult height Final height Thelarche Prepuberty Puberty Safety charmianq@gmail.com Targeted questions on case report forms were used to assess occurrence of the following...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Juvenile Paget disease Denosumab Bisphosphonates Growth hormone Linear growth Height velocity Receptor activator of nuclear factor-κB ligand Juvenile Paget...

...Denver D. Brown; Andrew Dauber Poor growth is a common finding in children with chronic kidney disease (CKD) that has been associated with poor long-term outcomes. The etiology of poor growth in this population is multifactorial and includes dysregulation of the growth hormone (GH) and insulin-like...

...Elodie Adler; Anne-Sophie Lambert; Claire Bouvattier; Cécile Thomas-Teinturier; Anya Rothenbuhler; Paul de Boissieu; Agnès Linglart Introduction: About 8% of children born small for gestational age (SGA) do not reach a final height within the normal range. Recombinant human growth hormone (rhGH...